GLP-1 medications are reshaping medical weight loss, with Tirzepatide leading the current market while Retatrutide emerges as a promising new contender
Researchers also looked at the risk that patients might be diagnosed with biliary disease, which is a cluster of problems affecting the gallbladder and bile ducts, but there were no significant differences between the groups
Nevertheless, no difference of hypoglycemia risks among all the GLP-1RAs was revealed by the review, indicating no difference of hypoglycemia rate exists between long-acting and short-acting (3)
The distribution of prescription drugs, such as Ozempic, over the internet is banned
While PCOS is not considered a criterion for MASLD screening in published guidelines, this condition typically manifests with other cardiometabolic risk factors that would merit MASLD screening
This guide covers everything you should know about injecting semaglutide for weight loss